Manidón

Verapamil hydrochloride, the active ingredient in Manidón, is a calcium channel blocker presented as an injectable solution for intravenous use. It is employed to manage hypertension, angina pectoris, atrial fibrillation and supraventricular tachycardia in adult patients. GNH USA supplies Manidón as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Verapamil is used in cardiovascular conditions that benefit from calcium‑channel blockade. - Hypertension: lowers systemic blood pressure by reducing peripheral vascular resistance. - Angina pectoris: alleviates chest pain by decreasing myocardial oxygen demand through vasodilation. - Atrial fibrillation: helps control ventricular rate by slowing atrioventricular nodal conduction. - Supraventricular tachycardia: terminates rapid heart rhythms by inhibiting calcium influx in cardiac tissue.

Adverse reactions may occur with intravenous verapamil administration.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the lower limbs. - Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects: - Bradycardia: clinically significant slowing of heart rate. - Hypotension: marked drop in blood pressure requiring monitoring. - Cardiac conduction block: advanced AV block or heart block. - Allergic reaction: rash, urticaria, or anaphylaxis in rare cases.

Before using intravenous verapamil, consider the following safety measures. - Cardiac function: assess for existing heart block or severe left ventricular dysfunction. - Blood pressure: monitor closely in patients with baseline hypotension. - Drug interactions: review concomitant medications that affect cardiac conduction. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Verapamil may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Beta‑blockers: risk of severe bradycardia or AV block. - Digoxin: increased serum levels leading to toxicity. - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): markedly raise verapamil concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive blood pressure lowering effect. - Statins metabolised by CYP3A4 (e.g., simvastatin): may increase statin exposure. - Diuretics: potential for excessive hypotension when combined.